Get started

ACHV

ACHV Biotech ACHV had good earnings in mid-March and has been in an ascending triangle since that time. The uptrend had a correction April 17th to 20th to which buyers responded with spiking buying volume. Current volume is 3x relative to the usual and customary historical volume averages. I will take a long trade on this when price descends to the support trendline as notified by an alert set on Tradingview. The target is the post covid highs of $ 17.00 . This is modest compared with the average upside of the analysts of $ 22+ ( see the link below) I will take out a sizeable stock position and also some insurance in the form of a long term put option to manage the risk on the trade.
NASDAQ:ACHVLong
by AwesomeAvani
ACHV preparing to Reverse SHORTACHC previously ran up in a high tight flag pattern in my previous idea. It has been slowly ascending in a narrowing channel. ( ascending wedge) There has been a little push in volume on the indicator as price has approached the upper boundaries of the channel. The average directional index has decreased into the " chop zone" where consolidation and lack of direction describes the price action. I see this an an opportunity for a short entry. I will watch things on the 1 and 5 minute charts for the best entry possible and the ride this volatile biotechnology stock a long as possible.
NASDAQ:ACHVShort
by AwesomeAvani
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern" after a big uptrend to start the year. Earnings on Thursday 3/16 were quite favorable.On the relative volume indicator Friday, May 17th showed a paradoxical huge selling volume spike to finish out this week. ( I mislabelled this as upcoming on the chart) Paradoxically, the last earnings report in November was poor but resulted in strong upward price action. The MACD histogram is at the zero line. Will ACHV resume the uptrend after earnings? Was the selling volume an institutional trader fake out to set up a lower price to buy call options? According to Tip Ranks, the analysts give ACHV a high rating with significant upside. See the link below Who knows but this may be worth watching for signs of buying volume and accumulation to fuel bullish momentum.
NASDAQ:ACHV
by AwesomeAvani
1
ACHV | Time to Start Loading | LongAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
NASDAQ:ACHVLong
by DivergenceSeeker
Achieve Life Sciences Inc 🧙Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ACHVLong
by unfair_advantage
1
Achieve Life Sciences Inc 🧙Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ACHVLong
by unfair_advantage
ACHV Achieve Life Sciences 10X potential! Highest undervalued!On 8/7/2020 Brokerage LADENBURG THALM/SH SH Reiterated ACHV Rating to BUY and set the target price to $100.00, now the cost of one share is 9.84usd. You can find the asset on trading212, the most downloaded trading app in the U.K. With a market cap of $15.45 million and a worldwide working product, it`s hard to say ACHV can go lower than that. The only concern is how much upside potential does it have. On July 31 ACHIEVE ANNOUNCES PATENT GRANTED IN THE U.S. FOR NOVEL ANALOGS OF CYTISINICLINE FOR USE IN CNS AND ADDICTION INDICATIONS. Also Short Interest in Achieve Life Sciences Inc Drops By 81.1%. Achieve Life Sciences issued its quarterly earnings results on Aug 4th. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.80) by $2.12, Fidelity Earnings reports. If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:ACHVLong
by TopgOptions
2
Would you buy this? ACHV Look at the volume!On July 31th : Achieve Life Sciences receives U.S. patent for its novel analogs of cytisinicline for use in prevention or treatment of CNS and addictive disorders. Aimed at regaining compliance with Nasdaq's $1 minimum bid price listing requirement, Achieve Life Sciences has executed a 1:20 reverse split of its common stock. Achieve Life Sciences is scheduled to be releasing its earnings data after the market closes on Thursday, August 6th. Analysts expect Achieve Life Sciences to post earnings of ($0.19) per share for the quarter. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:ACHVLong
by TopgOptions
2
ACHV - DAILY CHARTHi, today we are going to talk about Achieve Life Sciences and its current landscape. Achieve Life Sciences has been surrounded by increasing speculation over its shares after a couple of days ago had unveiled an update on the cytisinicline (a drug to aid smoking cessation ) clinical development program, as the FDA had agreed with the overall Phase 3 study designed by the company, that now can start this phase program on the first half of 2020. Despite the recent decline in the number of adults that currently smoke cigarettes in the United States, the company product has room to thrive as 34 million* American adults still smokes, and the public health effort works in favor to reduce this number and incentivize the smokers to look into methods to drop this addiction. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. *CDC data - 2018 Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NASDAQ:ACHV
by Igor-Silva